Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and im...
Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade
About this item
Full title
Author / Creator
Nielsen, Sebastian R. , Strøbech, Jan E. , Horton, Edward R. , Jackstadt, Rene , Laitala, Anu , Bravo, Marina C. , Maltese, Giorgia , Jensen, Adina R. D. , Reuten, Raphael , Rafaeva, Maria , Karim, Saadia A. , Hwang, Chang-Il , Arnes, Luis , Tuveson, David A. , Sansom, Owen J. , Morton, Jennifer P. and Erler, Janine T.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Pancreatic ductal adenocarcinoma (PDAC) patients have a 5-year survival rate of only 8% largely due to late diagnosis and insufficient therapeutic options. Neutrophils are among the most abundant immune cell type within the PDAC tumor microenvironment (TME), and are associated with a poor clinical prognosis. However, despite recent advances in unde...
Alternative Titles
Full title
Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_80c3347050694832b4503df3a10d5b8d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_80c3347050694832b4503df3a10d5b8d
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-021-23731-7
